“Deucravacitinib Long-Term Efficacy Through 4 Years in Week 16 Placebo Crossover Patients in the Phase 3 POETYK PSO-1, PSO-2, and LTE Program”. SKIN The Journal of Cutaneous Medicine, vol. 8, no. 6, Nov. 2024, p. s422, https://doi.org/10.25251/skin.8.supp.422.